| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 24 Sept 2025 |  Annual General Meeting | NA | 24 Sept 2025 | 662.85 | 651.65 |
| 02 Sept 2022 |  Dividend | ₹ 0.60 /share | 01 Sept 2022 | 355.25 | 355.05 |
| 15 Sept 2023 | Dividend | ₹ 0.60 /share | 15 Sept 2023 | 257.55 | 292.40 |
| 21 Sept 2024 | Dividend | ₹ 0.80 /share | 20 Sept 2024 | 360.75 | 630.75 |
| 27 Sept 2024 | Annual General Meeting | NA | 27 Sept 2024 | 627.75 | 588.85 |
| 28 Oct 2024 |  Quarterly Result Announcement | NA | 28 Oct 2024 | 555.10 | 547.30 |
| 24 Jan 2025 | Quarterly Result Announcement | NA | 24 Jan 2025 | 669.40 | 730.35 |
| 27 May 2025 | Quarterly Result Announcement | NA | 27 May 2025 | 701.60 | 742.45 |
| 13 Aug 2025 | Quarterly Result Announcement | NA | 13 Aug 2025 | 658.25 | 651.90 |
| 05 Sept 2025 | Dividend | ₹ 1.00 /share | 04 Sept 2025 | 742.45 | 655.60 |
Supriya Lifescience
651.55
-4.05
(-0.62%)
Market Cap
5,243.86 Cr
EPS
23.35
PE Ratio
29.63
Dividend Yield
0.15 %
Industry
Healthcare52 Week High
842.00
52 Week Low
511.40
PB Ratio
5.29
Debt to Equity
0.02
Sector
Pharmaceuticals
Company News
View All News
Supriya Lifescience aims to achieve EBITDA margins of 33-35% in FY26 with 20% year-on-year revenue growth, targeting Rs 1,000 crore by FY27. Executive Chairman Satish Waman Wagh outlined a strategy involving launching 3-4 new products annually, expanding into the US market, and challenging Chinese competitors. The company launched a new anaesthetic product targeting a $300 million market and is in discussions with multinational corporations for a product with $7 billion market potential. Capital expenditure is planned at Rs 65-70 crore for the current year, with Rs 200 crore allocated over three years for the new Patalganga site in Maharashtra. The company focuses on regulated markets with USFDA-compliant manufacturing and backwards integration to maintain cost efficiencies against Chinese competition.
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,593.60 | #1 3,82,358.02 | 33.10 | #1 54,729.00 | 9.71 | #1 10,980 | -19.84 | 39.45 | |
6,009.00 | 1,59,520.07 | 70.63 | 9,712.00 | 18.67 | 2,191 | 26.74 | 43.85 | |
1,553.40 | 1,25,469.33 | 23.63 | 28,409.50 | 7.12 | 5,291 | 9.88 | 57.67 | |
3,579.10 | 1,21,133.01 | 60.27 | 11,539.40 | 6.99 | 1,911 | 19.91 | 51.53 | |
1,268.10 | 1,05,831.96 | #1 18.41 | 33,741.20 | 16.73 | 5,725 | 1.26 | 48.40 | |
2,550.60 | 1,05,270.59 | 56.03 | 12,744.20 | #1 20.90 | 2,007 | -18.14 | 55.83 | |
1,013.85 | 1,02,017.03 | 21.84 | 23,511.00 | 18.55 | 4,615 | 2.60 | 60.44 | |
1,943.90 | 88,777.03 | 23.95 | 22,909.50 | 13.74 | 3,306 | #1 51.64 | 50.97 | |
31,150.00 | 66,191.58 | 47.11 | 6,684.70 | 9.64 | 1,414 | 11.55 | 45.41 | |
5,333.50 | 63,769.99 | 27.89 | 13,458.30 | 3.70 | 2,216 | 21.39 | 57.64 |
Forecast
Actual
Corporate Action
Technical Indicators
RSI(14)
Neutral 42.39
ATR(14)
Less Volatile 20.75
STOCH(9,6)
Neutral 26.62
STOCH RSI(14)
Neutral 24.08
MACD(12,26)
Bearish -0.36
ADX(14)
Weak Trend 15.23
UO(9)
Bearish 41.07
ROC(12)
Downtrend And Accelerating -3.79
WillR(14)
Oversold -83.13
Mutual Fund Holdings
ITI Large & Mid Cap Fund Direct-Growth 
Motilal Oswal Nifty Microcap 250 Index Fund Direct - Growth 
Quantum Small Cap Fund Direct - Growth 
WhiteOak Capital Pharma and Healthcare Fund Direct - Growth 
Samco Multi Cap Fund Direct-Growth 
Groww Nifty Total Market Index Fund Direct - Growth 
Bandhan BSE Healthcare Index Fund Direct-Growth 
Angel One Nifty Total Market Index Fund Direct - Growth 
Mirae Asset Nifty Total Market Index Fund Direct-Growth 
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
